Husband and wife Ken Deutsch and Amy Green have each had to grapple with cancer, as well as multiple setbacks and even recurrences.

New study looks at long-term impacts in people with prostate, bladder, colorectal and lung cancers

Tumors with large numbers of genetic mutations may be especially susceptible to treatment with immunotherapy.

The 30% improvement in survival has brought a Phase III trial to an early halt.

The antibody-drug conjugate nearly doubled survival time for people with triple-negative breast cancer.

The immunotherapy is now approved for people whose cancer has not progressed on platinum-based chemotherapy.

“Potentially practice-changing” data show patients with advanced urothelial carcinoma survive longer with immune-boosting drug after chemo.